Document is current
Any future updates will be listed below
-
Authors
Rudofsky, Gottfried https://orcid.org/0000-0002-2576-7190
Amadid, Hanan
Braae, Uffe Christian https://orcid.org/0000-0002-2743-4584
Catrina, Sergiu-Bogdan
Kick, Anastas
Mandavya, Kabirdev https://orcid.org/0000-0003-3046-4503
Roslind, Klaus
Saravanan, Ponnusamy https://orcid.org/0000-0002-9566-2626
van Houtum, William
Jain, Akshay B.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04559815 at ClinicalTrials.govnct04537637 at ClinicalTrials.govDocuments that mention this clinical trial
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
https://doi.org/10.1007/s13300-024-01668-6
nct05230615 at ClinicalTrials.govDocuments that mention this clinical trial
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
https://doi.org/10.1007/s13300-024-01668-6
nct04601740 at ClinicalTrials.govDocuments that mention this clinical trial
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
https://doi.org/10.1007/s13300-024-01668-6
PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes
https://doi.org/10.1007/s13300-025-01719-6
nct04601753 at ClinicalTrials.govDocuments that mention this clinical trial
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study
https://doi.org/10.1007/s13300-024-01588-5
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
https://doi.org/10.1007/s13300-024-01668-6
nct04537624 at ClinicalTrials.govDocuments that mention this clinical trial
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
https://doi.org/10.1007/s13300-024-01668-6
PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice
https://doi.org/10.1007/s13300-024-01614-6
nct04862923 at ClinicalTrials.govDocuments that mention this clinical trial
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study
https://doi.org/10.1007/s13300-023-01525-y
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
https://doi.org/10.1007/s13300-024-01668-6
Documents that mention this clinical trial
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
https://doi.org/10.1007/s13300-024-01668-6
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 7 October 2024
Accepted: 28 October 2024
First Online: 13 November 2024
Declarations
:
: Gottfried Rudofsky: receives lecture fees from Novo Nordisk. Hanan Amadid: employee and shareholder of Novo Nordisk A/S. Uffe C. Braae: employee and shareholder of Novo Nordisk A/S. Sergiu-Bogdan Catrina: No conflict of interest. Anastas Kick: Lecture/other fees from NovoNordisk and Abbott. Kabirdev Mandavya: employee of Novo Nordisk A/S. Klaus Roslind: Honorarium/Moderator at Novo Nordisk meetings. Ponnusamy Saravanan: International Doctoral Training scholarship Grant from Novo Nordisk; PhD studentship funding from BHR Pharmaceuticals, UK; Joint MRC—Abbott project grant for Magic study; Lecture/other fees from Novo Nordisk, Sanofi, Lilly, Boehringer, Abbott. William van Houtum: No conflict of interest. Akshay B. Jain: Grants from Abbott, Amgen, Novo Nordisk; Honorarium from Abbott, AstraZeneca, Amgen, Bausch Healthcare, Bayer, Boehringer Ingelheim, Care to Know, CCRN, Connected in Motion, CPD Network, Dexcom, Diabetes Canada, Eli Lilly, GSK, HLS Therapeutics, Janssen, Master Clinician Alliance, MDBriefcase, Merck, Medtronic, Moderna, Novartis, Novo Nordisk, Partners in Progressive Medical Education, Pfizer, Timed Right, WebMD; Lecture/other fees from Abbott, AstraZeneca, Amgen, Bausch Healthcare, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Gilead Sciences, GSK, HLS Therapeutics, Insulet, Janssen, Medtronic, Novartis, Novo Nordisk, Partners in Progressive Medical Education, Pfizer, PocketPills, Roche, Takeda, Ypsomed.
: The PIONEER REAL study protocols were approved by local independent ethics committees (IEC), institutional review boards (IRB) or equivalent authorities, and studies were conducted following good pharmacoepidemiology practices (GPP) [] and good pharmacovigilance practices (GVP) [] in accordance with the Declaration of Helsinki []. All participants signed an informed consent.
